Idogen Running Out Of Survival Options
Swedish Firm Seeking Reverse Merger Solution
With very little cash left in the bank, Idogen is weighing up its options including a reverse merger or liquidation.
You may also be interested in...
The Swedish biotech is expecting intense discussions with prospective partners for mitazalimab, a couple of years after Janssen returned the rights to the CD40 agonist.
When it comes to building innovative pipelines and raising cash, Scandinavia is giving the rest of Europe a run for its money.
Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of semaglutide, describes the unprecedented growth of the obesity market and what might come next for Novo.